ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

DRCCA Board Changes Center Core Grants Guidelines To Permit Payment for Control Program Directors

October 29, 1982

In Brief: ASCO awards career development grants.

May 21, 2004

“Projects For Special Donors” – ACS Considering Way To Raise Vast New Sums For Cancer Program

March 31, 1978

NCI, Dialogue Plan A National Tissue Bank

July 11, 2003

SWOG Trial Reports Longest Survival To Date For NSCLC

June 29, 2001

NCI To Lose 19% of Workforce Over Six Years, Broder Says

November 4, 1994